WATCH: Timelapse video of progress on North East's new eye hospital
The new Sunderland Eye Infirmary is set to open in summer 2026 and will serve patients from across the North East and North Cumbria.
A time-lapse video of the build has been released to mark the one-year milestone, showing progress since construction began 18 months ago.
Construction began in December 2023 and the internal fit-out is now well underway.
Dr Ajay Kotagiri, clinical director of ophthalmology services at South Tyneside and Sunderland NHS Foundation Trust, said: "It was brilliant to visit the new hospital site and amazing to see the actual space we will be working in from next summer.
"The clinical areas are so spacious and well designed and we can't wait to be able to see and treat patients in this fantastic new facility."
The new hospital will house all current clinical services from the Queen Alexandra Road site, including the Cataract Treatment Centre, which plays a key role in reducing waiting lists across the region.
Ophthalmology remains one of the busiest services in the NHS, with many people experiencing sight problems during their lives.
Alongside the construction, the Trust's STS Charity has launched the Vision Appeal, aiming to raise £1 million to fund advanced technology and equipment beyond what is included in the hospital build.
Dr Kotagiri said: "Our Vision Appeal is a great way for patients and local people to get involved with the new Eye Hospital and be part of something fantastic.
"We want to stay at the forefront of eye research and innovation in Sunderland and the STS Charity's support will help us do that.
"It will help us to fund equipment and technology, over and above what we already have."
The new hospital forms part of the Riverside Sunderland development and is being built by Kier in partnership with Sunderland City Council.
READ MORE:
Rare breed of horse cherished by the late Queen joins Bishop Auckland theatre show
Town to step out in style for ball in memory of 'much-loved' Grace and Wendy
Plans to transform Grade II-listed church into housing, offices, and gym approved
Councillor Kevin Johnston, cabinet member for business, housing and regeneration, said: "It's fantastic to see work progressing apace on the new Eye Hospital at Riverside Sunderland.
"Once complete, this world-class facility will be one of the few standalone specialist eye hospitals anywhere in the UK and the region's only dedicated specialist centre for ophthalmology care."
The hospital will also include wellbeing rooms, a café overlooking the River Wear, and a children's area with dedicated waiting and treatment rooms.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
an hour ago
- Wall Street Journal
Do We Need to Make Coca-Cola Great Again?
Your editorial states that President Trump is pressing Coca-Cola to use cane sugar instead of corn syrup and that Health Secretary Robert F. Kennedy Jr. has said that corn syrup can cause obesity and diabetes ('Trump, Coke and the Sugar Cartel,' Review & Outlook, July 24). Why is Mr. Trump concerned with Coca-Cola? How does he know that Coke is better with cane sugar, when he reportedly drinks 12 cans of Diet Coke each day? Diet Coke contains aspartame, an artificial sweetener, and Mr. Kennedy has repeatedly stated that artificial sweeteners are detrimental to one's health. Is Mr. Trump going to give up Diet Coke? Is he going to press Coca-Cola to change the sweetener in Diet Coke?
Yahoo
an hour ago
- Yahoo
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
Key Points Novo Nordisk and Regeneron have encountered challenges recently. Both companies are significantly trailing the market this year. These healthcare leaders still could perform well in the long run. 10 stocks we like better than Novo Nordisk › Even with all the volatility and the flirting with bear-market territory, the S&P 500 index is well in the green this year, up about 8% since early January. Some stocks haven't been so lucky, though. Novo Nordisk (NYSE: NVO) and Regeneron Pharmaceuticals (NASDAQ: REGN), two leading drugmakers, have underperformed for most of the year, significantly lagging the broader market. These healthcare giants are facing some headwinds, but does that mean investors should steer clear of them? Let's find out. 1. Novo Nordisk Novo Nordisk has been facing several challenges that predate this year. It encountered a clinical setback for what Wall Street thought was a promising weight management candidate. Furthermore, the company's financial results, although strong when compared to its similarly sized peers, were not seen as sufficient because it's held to a higher standard. These challenges have led to a terrible performance this year. Novo Nordisk's shares are down by 18% year to date, significantly lagging the S&P 500. However, the stock might be a steal right now. The company has made several moves that should allow it to recover. Novo Nordisk's pipeline, especially in diabetes and weight management, remains one of the strongest in the industry. It recently initiated a phase 3 study for amycretin -- its next-generation GLP-1 medicine -- in both subcutaneous and oral formulations. It requested regulatory approval in the U.S. for an oral version of semaglutide, its well-known medicine marketed as Wegovy for weight loss and as Ozempic for diabetes management. Novo Nordisk has also penned several licensing deals that have expanded its pipeline in weight management. The company should launch at least one new medicine in its core therapeutic area within the next few years. Financial results should remain strong as Ozempic and Wegovy continue driving solid revenue growth. Considering the stock's sell-off over the past years, shares now look more than reasonably valued relative to Novo Nordisk's growth potential. Their forward price-to-earnings ratio of 16.9 is in line with the healthcare industry's average of 16.5 as of this writing. However, Novo Nordisk typically grows its revenue and earnings faster than its peers. That makes its stock attractive at current levels, based on its growth potential. 2. Regeneron Pharmaceuticals Regeneron is facing biosimilar competition for Eylea, a medicine for wet age-related macular degeneration that was once one of its biggest growth drivers. Sales of the medicine have dropped, dragging total revenue down with them. That's the most important reason why Regeneron's shares are down by 19% since the year started. However, the stock is still attractive. The biotech might go through a period of its top line declining, but it can still recover. Here are three reasons why. First, the company's newer, higher-dose (HD) formulation of Eylea is taking market share away from its previous version. HD Eylea is performing well and will grow even faster once it earns some label expansions. Second, Regeneron has a deep pipeline that's expected to yield new brand approvals. Earlier this month, it earned the green light for Lynozyfic, a cancer medicine, in the U.S. One of its more promising candidates is a gene therapy for one type of genetic deafness, which is showing incredible potential in clinical trials. Regeneron should move beyond Eylea thanks to newer approvals. Third, the company's most important product, Dupixent, an eczema treatment, is performing exceptionally well. The medicine has earned important label expansions in recent years, including in treating chronic obstructive pulmonary disease (COPD) and a rare skin condition called bullous pemphigoid. Dupixent will maintain its upward growth trajectory for a while. Here's one more reason to invest in Regeneron: The company is committed to returning capital to shareholders. It recently initiated a dividend and has a robust share-buyback program in place. The stock might be moving in the wrong direction right now, but those willing to hold onto it for five years or more could see superior returns over the long run. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Are Losing to the S&P 500 This Year was originally published by The Motley Fool Connectez-vous pour accéder à votre portefeuille
Washington Post
3 hours ago
- Washington Post
NIH cuts spotlight a hidden crisis facing patients with experimental brain implants
Carol Seeger finally escaped her debilitating depression with an experimental treatment that placed electrodes in her brain and a pacemaker-like device in her chest. But when its batteries stopped working, insurance wouldn't pay to fix the problem and she sank back into a dangerous darkness. She worried for her life, asking herself: 'Why am I putting myself through this?'
